MarketPeel
Insider Trading Intelligence
Pricing
…
TS

Timothy Eugene Sullivan

APLS
CHIEF FINANCIAL OFFICER · APELLIS PHARMACEUTICALS, INC. · CIK 0001707000
FILING MIX · LIFETIME35%/65%
BUYS
34
SELLS
63
TOTAL VALUE
$18.46M
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
29,070
AVG SELL PX
$56.53
TRADE KIND
SHOWING 97 / 97
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
23 backtested trades · 8 horizons · 19 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Timothy Eugene Sullivan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d23+39.13%+1.25%+0.93%+0.33%-0.67%—
14d23+69.57%-3.18%+1.40%-4.58%-4.56%—
30d23+69.57%-4.19%+2.08%-6.26%-5.83%—
60d23+91.30%-26.20%+1.38%-27.59%-22.10%—
90d23+78.26%-13.88%+2.35%-16.23%-30.05%—
180d23(3 pending)+95.00%-30.88%+9.17%-40.05%-41.09%—
1y23(6 pending)+100.00%-47.73%+22.25%-69.98%-77.98%—
2y23(10 pending)+100.00%-67.29%+42.62%-109.92%-113.19%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
APLS · 29,070 shares · as of May 14, 2026
089,655179,310268,964358,619202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 34 buys / 63 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
30,620——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
41,250——41,250May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
232,903——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
60,242——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
34,533——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
82,500——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
34,447——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
6,872——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
11,874——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
45,000——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
23,958——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
84,946——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
30,620——30,620May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
29,070——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
71,492——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
41,250——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
140,945——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
58,140——58,140May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
43,183——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
70,125——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
58,140——0May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
29,070——29,070May 14, 2026May 14, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
11,096——71,492Apr 17, 2026Apr 20, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
11,096——140,945Apr 17, 2026Apr 20, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
58,140——152,041Jan 28, 2026Jan 30, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
10,287$21.77$223.9K93,901Jan 22, 2026Jan 23, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,892$19.79$57.2K104,188Jan 20, 2026Jan 21, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,856$22.19$85.6K107,080Jan 13, 2026Jan 15, 2026 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
10,000——232,903Oct 21, 2025Oct 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
10,000$10.03$100.3K120,936Oct 21, 2025Oct 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,000$28.03$280.3K110,936Oct 21, 2025Oct 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
10,000$27.83$278.3K60,396Sep 8, 2025Sep 10, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
15,000——242,903Sep 8, 2025Sep 10, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
32,729$27.86$911.8K110,936Sep 8, 2025Sep 10, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
15,000$10.03$150.4K143,665Sep 8, 2025Sep 10, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
82,500$19.39$1.60M82,500Jun 9, 2025Jun 11, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
546$29.52$16.1K128,665Jan 29, 2025Jan 30, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,088$30.43$94.0K129,211Jan 22, 2025Jan 23, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
45,929——132,299Jan 21, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,730$29.96$51.8K86,370Jan 17, 2025Jan 21, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,170$28.70$62.3K88,100Jan 13, 2025Jan 14, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
10,054——84,946Dec 31, 2024Jan 3, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
10,054$13.85$139.2K90,270Dec 31, 2024Jan 3, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
1,042$14.95$15.6K80,216Dec 31, 2024Jan 3, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,042——23,958Dec 31, 2024Jan 3, 2025 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
14,164——79,174Apr 18, 2024Apr 19, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
14,164——70,396Apr 18, 2024Apr 19, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,000$58.66$234.6K93,338Apr 1, 2024Apr 2, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
4,000$10.03$40.1K97,338Apr 1, 2024Apr 2, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
4,000——257,903Apr 1, 2024Apr 2, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,000$63.95$127.9K93,338Mar 1, 2024Mar 5, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
6,000$10.03$60.2K99,338Mar 1, 2024Mar 5, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,000$62.86$251.4K95,338Mar 1, 2024Mar 5, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
6,000——261,903Mar 1, 2024Mar 5, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,431$67.77$97.0K93,338Feb 12, 2024Feb 13, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
906$64.14$58.1K94,769Jan 29, 2024Jan 31, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,551$65.00$230.8K95,675Jan 22, 2024Jan 23, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,533$66.30$2.29M34,533Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,235$66.81$149.3K99,226Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
23,748——101,461Jan 16, 2024Jan 17, 2024 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
14,158——267,903Nov 30, 2023Dec 1, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
14,158$10.03$142.0K91,871Nov 30, 2023Dec 1, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
300$54.79$16.4K77,713Nov 30, 2023Dec 1, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
13,858$54.73$758.4K78,013Nov 30, 2023Dec 1, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
30,609$87.79$2.69M115,283Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
30,506$89.83$2.74M77,713Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,600$90.60$145.0K145,892Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
69,779——288,840Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
7,064$88.36$624.2K108,219Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
69,779$10.03$699.9K147,492Jun 5, 2023Jun 6, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
20,000——56,232May 3, 2023May 3, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
20,000——77,713May 3, 2023May 3, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Gift
36,232——36,232Apr 19, 2023Apr 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALEGRANT
Gift
36,232——97,713Apr 19, 2023Apr 20, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
974$58.50$57.0K133,945Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,683——134,919Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,572——16,572Feb 21, 2023Feb 21, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
975$51.21$49.9K123,236Feb 10, 2023Feb 14, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
551$52.77$29.1K124,211Jan 27, 2023Jan 30, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,379$52.05$123.8K124,762Jan 20, 2023Jan 24, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
43,183$52.66$2.27M43,183Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
27,488——127,141Jan 12, 2023Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,750——99,653Apr 25, 2022Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
22,500——0Apr 25, 2022Jan 17, 2023 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
875$47.12$41.2K103,403Feb 10, 2022Feb 11, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
650$38.59$25.1K104,278Jan 28, 2022Jan 31, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
30,787——104,928Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
43,670——43,670Jan 21, 2022Jan 25, 2022 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
39,880——358,619Jun 8, 2021Jun 9, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
39,880$10.03$400.0K74,141Jun 8, 2021Jun 9, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
858$47.72$40.9K34,261Feb 10, 2021Feb 11, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,500——31,369Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,750——35,119Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
22,500——22,500Jan 28, 2021Jan 29, 2021 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,688——23,387Feb 10, 2020Feb 12, 2020 ↗View →
APLS
APELLIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
70,125——70,125Feb 10, 2020Feb 12, 2020 ↗View →
Other insiders · APLS
Loading peer insiders…
About this filer
CIK 0001707000
ROLE
Chief Financial Officer
PRIMARY
APLS
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001707000DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback